PLURI INC. (PLUR)
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
📉 **NEGATIVE** • Medium confidence analysis (69%) • Mild negative signal • Limited downside risk **Sentiment:** Negative (5%) **Content type:** General